$55 Million California Investment: First Patient Receives Viacyte Diabetes Device
Viacyte's diabetes device
San Diego U-T photo
The California stem cell agency and Viacyte, Inc., today marked a diabetic and stem cell first.
The first of about 40 patients has received the San Diego firm’s human embryonic stem cell device as part of a clinical trial testing what could be a virtual cure for type 1 diabetes.
The stem cell agency, which has i…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.